Journal article
Nintedanib Reduces Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Results of the SENSCIS Trial
- Distler, O. Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
- Highland, K.B. Respiratory Institute, Cleveland Clinic, Cleveland, OH, United States
- Gahlemann, M. Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland
- Azuma, A. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
- Fischer, A. University of Colorado School of Medicine, Denver, CO, United States
- Mayes, M.D. Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, United States
- Raghu, G. University of Washington, Seattle, WA, United States
- Sauter, W. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
- Girard, M. Boehringer Ingelheim France S.A.S., Reims, France
- Alves, M. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
- Clerisme-Beaty, E. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
- Stowasser, S. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
- Tetzlaff, K. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, and Department of Sports Medicine, University of Tübingen, Tübingen, Germany
- Kuwana, M. Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
- Maher, T.M. National Heart and Lung Institute, Imperial College London, UK, and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, United Kingdom
- 2019-5-1
Published in:
- B17. ADVANCES IN ILD THERAPY. - American Thoracic Society. - 2019
- Language
-
- English
- Open access status
- closed
- Identifiers
- Persistent URL
- https://sonar.ch/global/documents/67390
Statistics
Document views: 22
File downloads: